ALKEM LABS UNIT TO BUY AT UP TO 55% OF OCCLUTECH HOLDING

ALKEM LABS UNIT TO BUY AT UP TO 55% OF OCCLUTECH HOLDING

Alkem Laboratories’ medical devices subsidiary, Alkem MedTech, has agreed to acquire a stake of up to 55% in Swiss medical device firm Occlutech Holding AG for €99.4 million ($118 million), marking its entry into the advanced cardiovascular devices sector. The transaction, subject to regulatory approvals and final agreements, is expected to close by June 2026. Occlutech specializes in minimally invasive devices for congenital heart disease and heart failure, positioning it as the second-largest player in Europe's cardiac implants market and the third-largest globally. The company operates manufacturing and R&D facilities in Germany and Turkey, a distribution hub in Sweden, and clinical operations in the United States.

Alkem MedTech’s CEO, Kaustav Banerjee, highlighted that the acquisition provides access to high-barrier, high-value markets such as the U.S., Japan, Germany, and Western Europe. This move aligns with broader industry trends of pharmaceutical companies diversifying into medical devices to capitalize on high-growth, technology-driven healthcare segments. Occlutech’s established international presence and product portfolio are expected to enhance Alkem's global footprint, complementing its existing pharmaceutical business.

The deal reflects strategic interest in structural heart technologies, a sector projected to grow significantly as demand for minimally invasive cardiac solutions rises. With the global medical devices market anticipated to exceed $1 trillion by 2034, Alkem’s investment underscores its ambition to expand beyond generics into higher-margin healthcare innovations.